Follow
Andrea Maria Gazzo
Andrea Maria Gazzo
Verified email at mskcc.org
Title
Cited by
Cited by
Year
PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update
V López-Ferrando, A Gazzo, X De La Cruz, M Orozco, JL Gelpí
Nucleic acids research 45 (W1), W222-W228, 2017
1792017
DEOGEN2: prediction and interactive visualization of single amino acid variant deleteriousness in human proteins
D Raimondi, I Tanyalcin, J Ferté, A Gazzo, G Orlando, T Lenaerts, ...
Nucleic acids research 45 (W1), W201-W206, 2017
882017
DIDA: A curated and annotated digenic diseases database
AM Gazzo, D Daneels, E Cilia, M Bonduelle, M Abramowicz, ...
Nucleic acids research 44 (D1), D900-D907, 2016
822016
Predicting disease-causing variant combinations
S Papadimitriou, A Gazzo, N Versbraegen, C Nachtegael, J Aerts, ...
Proceedings of the National Academy of Sciences 116 (24), 11878-11887, 2019
782019
Understanding mutational effects in digenic diseases
A Gazzo, D Raimondi, D Daneels, Y Moreau, G Smits, S Van Dooren, ...
Nucleic acids research 45 (15), e140-e140, 2017
432017
Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal CarcinomaSynchronous DCIS and Invasive Ductal Carcinoma
F Pareja, DN Brown, JY Lee, A Da Cruz Paula, P Selenica, R Bi, ...
Clinical Cancer Research 26 (14), 3682-3693, 2020
362020
Multilevel biological characterization of exomic variants at the protein level significantly improves the identification of their deleterious effects
D Raimondi, AM Gazzo, M Rooman, T Lenaerts, WF Vranken
Bioinformatics 32 (12), 1797-1804, 2016
322016
Cancer-causative mutations occurring in early embryogenesis
F Pareja, RN Ptashkin, DN Brown, F Derakhshan, P Selenica, ...
Cancer discovery 12 (4), 949-957, 2022
102022
Using game theory and decision decomposition to effectively discern and characterise bi-locus diseases
N Versbraegen, A Fouché, C Nachtegael, S Papadimitriou, A Gazzo, ...
Artificial intelligence in medicine 99, 101690, 2019
102019
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch SyndromeBreast Cancer in Patients with Lynch Syndrome
CJ Schwartz, EM da Silva, A Marra, AM Gazzo, P Selenica, VK Rai, ...
Clinical Cancer Research 28 (2), 404-413, 2022
52022
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer
EM da Silva, P Selenica, M Vahdatinia, F Pareja, A Da Cruz Paula, ...
NPJ Breast Cancer 7 (1), 43, 2021
52021
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
P Selenica, A Marra, NJ Choudhury, A Gazzo, CJ Falcon, J Patel, X Pei, ...
Annals of oncology 33 (12), 1284-1295, 2022
32022
Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma
TM D'Alfonso, F Pareja, A Da Cruz Paula, M Vahdatinia, A Gazzo, ...
The Journal of Pathology: Clinical Research 7 (2), 113-120, 2021
32021
210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET)+/-CDK 4/6 inhibition (CDK4/6i) in estrogen receptor …
A Marra, A Gazzo, A Gupta, P Selenica, EM Da Silva, F Pareja, X Pei, ...
Annals of Oncology 33, S632, 2022
22022
Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma
CW Ashley, A Da Cruz Paula, L Ferrando, R Gularte‐Mérida, ...
Histopathology 79 (2), 176-186, 2021
22021
Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications
J Veeraraghavan, FT Liao, T Gordon, P Selenica, S Nanda, L Qin, Y Zhu, ...
Cancer Research 82 (12_Supplement), LB517A-LB517A, 2022
12022
Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of …
J Veeraraghavan, S Bose, R Mistry, P Selenica, S Nanda, L Qin, A Gazzo, ...
Cancer Research 82 (4_Supplement), PD8-06-PD8-06, 2022
12022
Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and …
S Bose, R Mistry, CC Liu, S Nanda, L Qin, P Selenica, A Gazzo, Y Zhu, ...
Cancer Research 82 (4_Supplement), P4-01-01-P4-01-01, 2022
12022
KIT genetic alterations in breast cancer
M Vahdatinia, F Derakhshan, ADC Paula, H Dopeso, A Marra, AM Gazzo, ...
Journal of Clinical Pathology, 2022
2022
Cancer Causative Mutations Occurring in Early EmbryogenesisMosaicism in embryogenesis and cancer
F Pareja, RN Ptashkin, DN Brown, F Derakhshan, P Selenica, ...
Cancer Discovery, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20